The Promise That Couldn't Scale: What Sarepta's Elevidys Decline Reveals About Gene Therapy's Commercial Ceiling

There is a particular kind of disappointment that comes when a scientific breakthrough fails not in the laboratory, but in the marketplace. Sarepta Therapeutics is living through exactly that moment. Its gene therapy Elevidys, once heralded as a transformative treatment for Duchenne muscular dystrophy, is generating revenue that beats Wall Street estimates and still somehow sends the stock down more than 10 percent in a single session. That paradox tells you almost everything you need to know about where gene therapy stands commercially in 2026.

In its first-quarter earnings report, Sarepta posted $331 million in total net product revenue, above analyst expectations. Elevidys contributed $102 million of that, edging past the $95 million consensus estimate. On paper, a beat is a beat. But investors are not reading the headline number. They are reading the trajectory. Elevidys sales have been declining quarter over quarter, and no single quarterly beat changes the underlying story of a therapy that has been progressively constrained by regulatory action, safety concerns, and a shrinking eligible patient population.

A Therapy Caught Between Science and Regulation

The arc of Elevidys is a cautionary tale about the gap between clinical promise and commercial durability. The therapy received accelerated approval from the FDA in 2023 for ambulatory patients with Duchenne muscular dystrophy aged four and five. It was a landmark moment for the rare disease community. But the path since then has been turbulent. Safety concerns emerged, the therapy was temporarily pulled from the market, and the FDA ultimately restricted its use to a narrower patient population. Each regulatory action compressed the addressable market further.

Sarepta has also been restructuring aggressively. The company laid off more than a third of its workforce, halted several research programs, and pushed back debt obligations. CEO Doug Ingram, who guided the company through its most ambitious period of growth, announced plans to retire by the end of 2026. The combination of a shrinking product, a leaner organization, and a leadership transition creates an unusual kind of uncertainty for a company that was, not long ago, one of the most closely watched names in rare disease biotech.

The siRNA Pivot and What It Signals

What makes the Sarepta story analytically interesting is not the decline of Elevidys itself, but what the company is betting on next. Sarepta has licensed two small interfering RNA drugs from Arrowhead Pharmaceuticals, SRP-1001 and SRP-1003, targeting two distinct genetic conditions that cause muscle deterioration. Early data presented in March 2026 generated genuine interest on Wall Street, with shares rising on the day of the announcement. Analysts described the signals as promising but noted that the programs still need to demonstrate meaningful differentiation from existing approaches.

The pivot from gene therapy to RNA-based silencing is not incidental. It reflects a broader reassessment happening across the field. Gene therapies delivered via adeno-associated virus vectors have faced persistent challenges around durability, immune response, manufacturing complexity, and pricing. RNA-based approaches, by contrast, offer a different risk profile: they are reversible, they can be redosed, and the manufacturing infrastructure is increasingly mature. Alnylam Pharmaceuticals demonstrated with vutrisiran in ATTR cardiomyopathy that RNA silencing can deliver durable cardiovascular outcomes in a large Phase 3 trial. Sarepta appears to be drawing a similar lesson for the neuromuscular space.

The Broader Gene Therapy Reckoning

Sarepta is not alone in navigating the commercial limits of gene therapy. Across the sector, companies that achieved regulatory approval for gene therapies have found that approval and commercial success are not the same thing. Pricing at hundreds of thousands or millions of dollars per treatment creates access barriers that limit uptake. Payer negotiations are protracted. Long-term durability data remains incomplete for many approved products, creating hesitancy among physicians and patients alike.

The contrast with the scientific momentum in gene therapy is striking. Just weeks ago, the FDA granted accelerated approval to Regeneron's Otarmeni, the first gene therapy for genetic hearing loss, marking a genuine categorical advance in what medicine can do. Intellia Therapeutics reported positive Phase 3 results for its in vivo CRISPR therapy in hereditary angioedema. The science is advancing. The commercial infrastructure to support it is lagging.

This is the central tension that Sarepta's earnings report crystallizes. A company can beat estimates, maintain financial guidance of $1.2 to $1.4 billion in full-year net product revenue, and still see its stock fall sharply because investors have concluded that the current product is in managed decline and the next generation of products has not yet proven itself. That is a rational assessment, not a panic. It reflects the maturation of investor thinking about gene therapy as an asset class.

What Comes Next

For Sarepta, the next twelve months will be defined by the data readouts for SRP-1001 and SRP-1003, expected in the second half of 2026. If those programs deliver differentiated results, the company has a credible path to rebuilding investor confidence around a new platform. If they disappoint, the company faces a more difficult conversation about its long-term positioning in a competitive rare disease landscape.

For the gene therapy field more broadly, the Sarepta story is a useful corrective to the narrative that regulatory approval equals commercial success. The science of rewriting or silencing disease-causing genes has never been more sophisticated. The challenge now is building the commercial, regulatory, and access infrastructure that allows those scientific advances to reach patients at scale. Until that infrastructure matures, the gap between what gene therapy can do in a clinical trial and what it can sustain in the market will remain one of the defining tensions in biotech.